Navigation Links
Arthritis Foundation Announces Appointment of John Vernachio As Vice President of Research
Date:4/15/2013

ATLANTA, April 15, 2013 /PRNewswire-USNewswire/ -- The Arthritis Foundation announces the appointment of John Vernachio , Ph.D. as vice president of research effective April 15. In his new role he will provide leadership and direction to further the Arthritis Foundation research program and the organization's commitment to finding a cure and better, safer treatments for the nation's leading cause of disability. Vernachio will succeed Dr. John Hardin , who will assume a new role within the organization developing and implementing flagship initiatives in osteoarthritis.

(Photo: http://photos.prnewswire.com/prnh/20130415/DC95154 )

" John Vernachio is a world-class scientist and director in biotechnology with a proven track record," says Arthritis Foundation Chief Mission Officer, Jennifer Griffiths , Ph.D.  "I am confident that under his leadership the Arthritis Foundation will continue its legacy in driving targeted research initiatives that will push us toward a cure."

Vernachio brings to the Arthritis Foundation extensive research leadership and expertise, serving as a researcher and technical director in the biotechnology sector for more than 20 years. Most recently, he served as vice president of biology for Inhibitex, Inc.  Earlier, he held supervisory and leadership roles in several biotechnology companies including Baxter Healthcare and Valentis, Inc.  In addition, he is an author on over 20 peer-reviewed scientific articles, numerous scientific presentations and is a co-inventor on 10 patent applications.

A graduate of the University of Vermont, Vernachio earned a Bachelor of Science degree in Animal Science in 1984. He received a doctorate in biochemistry with a concentration in immunology and molecular biology in 1989 from Johns Hopkins University and completed his post-doctoral training in the Department of Immunology at The Research Institute of Scripps Clinic in San Diego in 1991.

About the Arthritis Foundation

Striking one in every five adults and 300,000 children, arthritis is the nation's leading cause of disability.  The Arthritis Foundation (www.arthritis.org) is committed to raising awareness and reducing the unacceptable impact of this serious and painful disease, which can severely damage joints and rob people of living life to its fullest.  The Foundation funds life-changing research that has restored mobility in patients for more than six decades; fights for health care policies that improve the lives of the millions who live with arthritis; and partners with families to provide empowering programs and information.


'/>"/>
SOURCE Arthritis Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. RI Hospital researchers discover new strategy to effectively treat, prevent osteoarthritis
2. Musculoskeletal Network Features New Research into the Cause of Rheumatoid Arthritis and Lupus
3. Targeting T cells in rheumatoid arthritis
4. WISE Surgical Solutions LLC Announces Project Hope: Helping People with Debilitating Conditions Including Arthritis, Parkinson's, MS and Spinal Injury Know Their Options
5. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
6. Musculoskeletal Network Features Update on Nutraceuticals for Osteoarthritis
7. July is not just about BBQ's; the Arthritis National Research Foundation honors Juvenile Arthritis Awareness Month
8. Riding to Cure Arthritis from New York to Oklahoma
9. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
10. Foundation For the NIH Joins NIH In Seeking Proposals to Study Sports-Related Brain Injuries
11. Physicians Endoscopy and Colon Cancer Challenge Foundation Partner to Raise Colon Cancer Awareness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ProMIS Neurosciences (“ProMIS” ... for neurodegenerative diseases, today announced it has issued a scientific white paper entitled ... of a series of commentaries from ProMIS’s scientific team offering insight into the ...
(Date:2/22/2017)... Dublin - Research and Markets has ... Market-By Type, By Application, By End User, By Region, By Country: ... ... Market is forecasted to grow at a CAGR of 11.33% during ... crop protection market is driven by the surging demand for less ...
(Date:2/22/2017)... ... February 22, 2017 , ... NDA Partners Chairman Carl ... Deputy Director in the FDA CDRH Division of Cardiovascular, Respiratory, and Neurological Devices ... as an Expert Consultant. , In Dr. Spyker’s accomplished career, he held positions ...
(Date:2/22/2017)... PARK, N.C., Feb. 22, 2017  United Therapeutics Corporation ... financial results for the fourth quarter and year ... financial results reflect continued growth as net revenues ... said Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... ability to develop and advance our growing product ...
Breaking Biology Technology:
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
(Date:1/24/2017)... NEW YORK , Jan. 24, 2017 /PRNewswire/ ... market study of the laboratory use of nuclear ... of 363 experienced end-users and profiled current practices, ... three years, as well as growth and opportunities. ... NMR, Instrument suppliers, NMR instruments, needs and innovation ...
(Date:1/19/2017)... SANTA CLARA, Calif. , Jan. 19, 2017 ... Valley company enhancing user experience and security for ... provider of next-generation payment processing systems and cybersecurity ... assist more banks, enterprises and financial institutions worldwide ... As part of the end-to-end secure user authentication ...
Breaking Biology News(10 mins):